Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 1652-1657, 2010.
Article
ي En
| WPRIM
| ID: wpr-241744
المكتبة المسؤولة:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>Evidence suggests that systemic inflammation may play an important role in the progression and morbidity of chronic obstructive pulmonary disease. It remains controversial whether inhaled corticosteroid in combination with a long-acting beta(2)-adrenoceptor agonist can attenuate systemic inflammation. We evaluated the effect of salmeterol/fluticasone propionate on circulating C-reactive protein level in stable chronic obstructive pulmonary disease patients.</p><p><b>METHODS</b>An open-label clinical trial was conducted to recruit 122 outpatients with stable moderate-to-severe chronic obstructive pulmonary disease from department of respiratory medicine in two teaching hospitals between June 2007 and March 2008. Patients were randomized into two groups (1:1) to receive either the combination of 50 microg salmeterol and 500 microg fluticasone twice daily (n = 61), or the combination of 206 microg albuterol and 36 microg ipratropium q.i.d (n = 61) over 6 months. Circulating C-reactive protein concentrations were measured before randomization and during the follow-up. The efficacy of treatment was also assessed by spirometry, as well as health status and dyspnea score at baseline and after 6-month treatment.</p><p><b>RESULTS</b>Baseline characteristics of two groups were similar. Compared with ipratropium/albuterol, the combination of salmeterol/fluticasone significantly reduced circulating level of C-reactive protein (-1.73 vs. 0.08 mg/L, respectively, P < 0.05) after 6-month treatment. Forced expiratory volume in one second (FEV(1)) and health status also improved significantly in salmeterol/fluticasone group compared with ipratropium/albuterol. Salmeterol/fluticasone treatment subjects who had a decrease of circulating C-reactive protein level had a significant improvement in FEV(1) and St George's Respiratory Questionnaire total scores compared with those who did not (185 vs. 83 ml and -5.71 vs. -1.79 units, respectively, both P < 0.01).</p><p><b>CONCLUSION</b>Salmeterol/fluticasone treatment reduced circulating C-reactive protein concentration in clinically stable moderate-to-severe chronic obstructive pulmonary disease patients after 6-month treatment.</p>
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
C-Reactive Protein
/
Treatment Outcome
/
Pulmonary Disease, Chronic Obstructive
/
Therapeutic Uses
/
Albuterol
/
Drug Therapy
/
Salmeterol Xinafoate
/
Fluticasone
/
Androstadienes
/
Metabolism
نوع الدراسة:
Clinical_trials
المحددات:
Female
/
Humans
/
Male
اللغة:
En
مجلة:
Chinese Medical Journal
السنة:
2010
نوع:
Article